Phase I, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study Evaluating Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JTK-853 in HCV Genotype 1 Infected Subjects, Followed by a Genotypic Resistance Monitoring Study.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2011
At a glance
- Drugs JTK 853 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- 22 Nov 2011 New trial record